TenNor Announces More than 300 Million RMB Financing to Support Development and Commercialization of Late-Stage Assets Including Rifasutenizol for Heliobacter pylori Infections
SUZHOU,China,Oct. 16,2024-- TenNor Therapeutics,a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases,announced today the initial closing of a Se